Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "Ibrutinib"

14 images for Ibrutinib

British Journal of Haematology, 2 weeks ago
MDLinx, 3 weeks ago
MDLinx, 3 weeks ago
MDLinx, 3 weeks ago
MDLinx, 3 weeks ago
MDLinx, 3 weeks ago
MDLinx, 3 weeks ago
MDLinx, 3 weeks ago
MDLinx, 3 weeks ago
MDLinx, 3 weeks ago

IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients

 Financial Content3 weeks ago Pharmacyclics' IMBRUVICA shows efficacy in previously untreated and relapsed/refractory high-risk CLL patients  Pharmaceutical Business Review3 weeks ago Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy In Previously Untreated And Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 1/5/2015  ClinicSpace3 weeks ago IMBRUVICA (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients  FirstWord Pharma3 weeks ago
[x]  

New Follow-Up Data for IMBRUVICA(R) (ibrutinib) Presented at ASH Show Longer Term Efficacy in Patients with Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma

/PRNewswire/ -- Data confirms consistency of IMBRUVICA as an effective treatment option for patients with these challenging blood cancers Janssen-Cilag International NV (Janssen) is pleased to announce the presentation of new longer term ...
 Individual.com1 month ago New follow-up data for IMBRUVICA® (ibrutinib) presented at ASH show longer term efficacy in patients with chronic lymphocytic Leukaemia and mantle cell lymphoma  European Pharmaceutical Review1 month ago
[x]  

Data Show High Response Rate to Ibrutinib Combination for Patients With Hard-to-Treat MCL

 HCPLive1 week ago

Janssen launches Imbruvica, first-in-class treatment for patients with Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL) in UK

Imbruvica® (ibrutinib), an oral, once-daily, first- in-class treatment, has been launched in the UK. It is specifically licensed for patients with relapsed or refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) who have ...
 Medical News Today1 month ago Janssen Launches Imbruvica in UK  PharmaAsia1 month ago Janssen launches Imbruvica®? (ibrutinib), first-in-class treatment for patients with Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL) in UK  PharmiWeb1 month ago

PHARMACYCLICS : New IMBRUVICA® ibrutinib Application Accepted by European Medicines Agency for Waldenstrom's Macroglobulinemia

By a News Reporter-Staff News Editor at Biotech Week -- Pharmacyclics, Inc. (NASDAQ: PCYC) announced the acceptance of a Type II variation application for IMBRUVICA(®) (ibrutinib) by the European Medicines Agency (EMA). This submission, filed by ...
 4 Traders1 month ago New IMBRUVICA® ibrutinib Application Accepted by European Medicines Agency for Waldenstrom's Macroglobulinemia  Pharmacy Choice1 month ago Funding to investigate an alternative to chemotherapy  Pharmacy Choice1 month ago

The Role of Extra-hepatic Metabolism in the Pharmacokinetics of Targeted Covalent Inhibitors Afatinib, Ibrutinib, and Neratinib

Abstract Despite the fact that much progress has been made recently in the development of targeted covalent inhibitors (TCIs), their pharmacokinetics (PK) have not been well characterized in the light of extra-hepatic ...
 Drug Metabolism And Disposition1 month ago

IMBRUVICA(R) (ibrutinib) in Combination with -2-

Patients who are prescribed IMBRUVICA can receive access support through a variety of programs: -- The YOU&i Start(TM) program enables eligible patients who are experiencing insurance coverage delays to access free product for a limited time. ...
 Scottrade1 month ago

Application submitted to the EMA to expand the therapeutic indication for IMBRUVICA® (ibrutinib) to include treatment of Waldenström's macroglobulinemia

Janssen-Cilag International NV (Janssen) announced today the submission of a Type II variation application to the European Medicines Agency (EMA) to vary the marketing authorisation for IMBRUVICA® (ibrutinib), to include a new therapeutic ...
 European Pharmaceutical Review1 month ago
Ecancer Medicalscience

ASCO publishes Clinical Cancer Advances 2015

by ecancer reporter Clare Sansom Since 2005, the American Society of Clinical Oncology (ASCO) has published an annual report detailing the main advances made in clinical cancer research during the last year. The 2015 report has now been ...
 Ecancer Medicalscience9 hours ago Leukemia Txs Top ASCO's Clinical Cancer Advances in 2015 List  Monthly Prescribing Reference4 days ago ASCO Reports Biggest Clinical Cancer Advances for 2015  Physicians Briefing4 days ago Better outlook for patients with CLL - four new treatments transform care  Medical News Today4 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less